Literature DB >> 25385728

Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy in bladder cancer: ready for prime time?

Damien Pouessel1, Hélène Gauthier1, Camille Serrate1, Christian Pfister2, Stéphane Culine3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25385728     DOI： 10.1200/JCO.2014.58.0498

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.

Authors:  Elisabeth E Fransen van de Putte; Laura S Mertens; Richard P Meijer; Michiel S van der Heijden; Axel Bex; Henk G van der Poel; J Martijn Kerst; Andries M Bergman; Simon Horenblas; Bas W G van Rhijn
Journal:  World J Urol       Date:  2015-07-17       Impact factor: 4.226

Review 2.  Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.

Authors:  Samuel A Funt; Jonathan E Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2016-11-22       Impact factor: 66.675

3.  FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy.

Authors:  E E Fransen van de Putte; E Vegt; L S Mertens; A Bruining; K Hendricksen; M S van der Heijden; S Horenblas; B W G van Rhijn
Journal:  Int Urol Nephrol       Date:  2017-07-03       Impact factor: 2.370

4.  C14orf166 is a high-risk biomarker for bladder cancer and promotes bladder cancer cell proliferation.

Authors:  Mingkun Chen; Yunlin Ye; Baojia Zou; Suping Guo; Fangjian Zhou; Keshi Lu; Jianye Liu; Zhenzhou Xu; Hui Han; Zhuowei Liu; Yonghong Li; Kai Yao; Cundong Liu; Zike Qin
Journal:  J Transl Med       Date:  2016-02-23       Impact factor: 5.531
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.